You are here: Industry Insights > Mavyret

News List

Changes to the Mavyret Product Label for Pediatrics americanpharmaceuticalreview
June 16, 2021
The FDA has approved Mavyret (glecaprevir and pibrentasvir) oral pellets (100mg/40mg) for the treatment of pediatric patients 3 to less than 12 years of age weighing less than 45 kg with chronic hepatitis C virus genotype 1, 2, 3, 4, 5, or 6 infection ...
FDA Warns of Liver Injury with Mavyret, Zepatier, Vosevi americanpharmaceuticalreview
September 03, 2019
The Food and Drug Administration (FDA) has received reports that the use of Mavyret, Zepatier, or Vosevi to treat chronic hepatitis C in patients with moderate to severe liver impairment has resulted in rare cases...
FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients drugs
May 06, 2019
FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients.
Global HCV Drug Market Declined to below USD10 Billion in 2018, with only AbbVie’s Mavyret Outshining PharmaSources/1℃
March 11, 2019
The global HCV drug market continued to shrink and reached USD7.767 billion in 2018.
AbbVie inks licensing deal to boost Mavyret access in nearly 100 countries fiercepharma
November 14, 2018
AbbVie has had success with its new pan-genotypic hepatitis C drug Mavyret, generating blockbuster-level sales at the expense of competitors.
As Humira competition nears, AbbVie's Imbruvica and Mavyret pick up steam fiercepharma
July 30, 2018
Even as AbbVie's megablockbuster immunology med Humira inches toward its first biosim competition, the drug is still churning out record sales.
Dogged by AbbVie's new share-stealing Mavyret, Gilead's hep C forecast comes in far short fiercepharma
February 09, 2018
Gilead Sciences' once-high-flying hepatitis C drugs have come a long way down since their peak sales years, but thanks to new competition from AbbVie, the company's important franchise will have another rough year in 2018.
FDA Approves Mavyret contractpharma
August 04, 2017
FDA Approves Mavyret (glecaprevir and pibrentasvir) for Hepatitis C